AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2018

Mar 29, 2018

32418_dirs_2018-03-29_f733dc98-821e-4368-bc92-2f782062bcc1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2018-03-27

Reporting Person: Jaksch Frank L Jr (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-27	Common Stock	M	24578	$4.5	Acquired	226135	Direct
2018-03-27	Common Stock	S	24578	$4.6	Disposed	201557	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-27	Employee Stock Options (right to buy)	$4.5	M	24578	Disposed	2018-04-21	Common Stock (24578)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2075052	Indirect

Footnotes

F1: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on March 16, 2018. The options exercised and sold were scheduled to expire on April 21, 2018.